The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: Results from the Québec Family Study

Clinical Genetics

Volumn 63, Issue 2, 2003, Pages 109-116

  Robitaille, J ^a,b   Despres J P ^a,b,c   Perusse L ^b   Vohl, Marie Claude ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

P12A polymorphism; Fat intake; Gene diet interaction; Metabolic syndrome; Obesity; PPAR

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; SATURATED FATTY ACID;

ADIPOSE TISSUE; ADULT; AGE; AGED; ALLELE; AMINO ACID SUBSTITUTION; ANTHROPOMETRIC PARAMETERS; ARTICLE; ATHEROGENESIS; BODY MASS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAMILY STUDY; FAT INTAKE; GENDER; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE HOMEOSTASIS; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; LIPID METABOLISM; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MODULATION; NUTRITION; PRIORITY JOURNAL; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

ADULT; ALLELES; BODY MASS INDEX; DIETARY FATS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; QUEBEC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0041630975     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2003.00026.x     Document Type: Article

References (34)

1. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999: 100: 123-128.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988: 37: 1595-1607.
3. Bouchard C, Perusse L, Rice T, Rao DC. The genetics of obesity. In: Bray G, Bouchard C, James W, eds. Handbook of obesity. New York: Dekker, 1998: 157-190.
4. Yen CJ, Beamer BA, Negri C et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997: 241: 270-274.
5. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998: 20: 284-287.
6. Beamer BA, Yen CJ, Andersen RE et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 1998: 47: 1806-1808.
7. Cole SA, Mitchell BD, Hsueh WC et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000: 24: 522-524.
8. Mori Y, Kim-Motoyama H, Katakura T et al. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998: 251: 195-198.
9. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999: 254: 450-453.
10. Bouchard C. Genetic epidemiology, association and sib-pair linkage: results from the Quebec Family Study. In: Bray GA, Ryan DH, eds. Molecular and genetic aspects of obesity. Baton Rouge: State University Press, 1996: 470-481.
11. Siri WE. The gross composition of the body. Adv Biol Med Phys 1956: 4: 239-280.
12. Callaway CW, Chumlea WC, Bouchard C, Himes JH, Lohman TG, Martin AD, Mitchell CD, Mueller WH, Roche AF, Seefeldt VD. Standardization of anthropometric measurements. In: Lohman T, Roche A, Martorel R, eds. The Airlie (VA) Consensus Conference Campaign, IL: Human Kinetics Publishers, 1988: 39-80.
13. Ferland M, Després JP, Tremblay A et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989: 61: 139-148.
14. Richterich R, Dauwalder H. Zur bestimmung der plasmaglukosekonzentration mit der hexokinase-glucose-6-phosphat-dehydrogenase-method. Schweiz Med Wochenschr 1971: 101: 615-618.
15. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971: 37: 732 738.
16. Rao DC, Province MA. The future of path analysis, segregation analysis, and combined models for genetic dissection of complex traits. Hum Hered 2000: 50: 34-42.
17. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000: 26: 76-80.
18. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001: 50: 2172-2176.
19. Douglas JA, Erdos MR, Watanabe RM et al. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001: 50: 886-890.
20. Mancini FP, Vaccaro O, Sabatino L et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999: 48: 1466-1468.
21. Mori H, Ikegami H, Kawaguchi Y et al. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001: 50: 891-894.
22. Hara K, Okada T, Tobe K et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000: 271: 212-216.
23. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J, Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999: 42: 892-895.
24. Luan J, Browne PO, Harding AH et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001: 50: 686-689.
25. Bonifacj C, Gerber M, Scali J, Daures JP. Comparison of dietary assessment methods in a southern French population: use of weighed records, estimated-diet records and a food-frequency questionnaire. Eur J Clin Nutr 1997: 51: 217-231.
26. Gibson RS. Principles of nutritional assessment. New York: Oxford University Press, 1990.
27. Centers for Disease Control and Prevention. Healthy People 2000 Review. Hyattsville, MD: National Center for Health Statistics, 1998.
28. Fleming RM. The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascular disease risk factors. Prev Cardiol 2002: 5: 110-118.
29. Weinsier RL, James LD, Darnell BE et al. Lipid and insulin concentrations in obese postmenopausal women: separate effects of energy restriction and weight loss. Am J Clin Nutr 1992: 56: 44-49.
30. Stevenson DW, Darga LL, Spafford TR, Ahmad N, Lucas CP. Variable effects of weight loss on serum lipids and lipoproteins in obese patients. Int J Obes 1988: 12: 495-502.
31. Rossner S, Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis 1987: 64: 125-130.
32. Schaefer EJ, Lichtenstein AH, Lamon-Fava S et al. Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. JAMA 1995: 274: 1450-1455.
33. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins a meta-analysis. Am J Clin Nutr 1992: 56: 320-328.
34. Xu HE, Lambert MH, Montana VG et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999: 3: 397-403.